ResearchHSR25-170: Investigating Socioeconomic and Racial Disparities in Pathologic Response and Survival Outcomes in Triple-Negative Breast Cancer Post-Neoadjuvant Chemotherapy
ResearchImmune and Metabolic Reprogramming Induced by Paclitaxel, Capecitabine and Eribulin in Breast Cancer: Insights into Therapeutic Targets
ResearchPaclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy
ResearchClinicopathological evaluation of triple-negative breast cancer treated with keynote-522 regimen
ResearchImpact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study
ResearchImmunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer
ResearchEpidemiology of early vs late recurrence among women with early stage estrogen receptor-positive breast cancer in the Pathways Study
ResearchInfiltration of Common Myeloid Progenitor (CMP) Cells is Associated With Less Aggressive Tumor Biology, Lower Risk of Brain Metastasis, Better Response to Immunotherapy, and Higher Patient Survival in Breast Cancer
ResearchSocial networks, social determinants, and mortality: Western New York Exposures and Breast Cancer study
ResearchTargeting the tumor microenvironment to improve clinical outcomes in triple negative breast cancer patients and bridge the current disparity gap
ResearchPotential association of SLCO1B1 and ABCB1 variant alleles with increased risk for palbociclib toxicity
ResearchUnder-Representation and Under-Reporting of Minoritized Racial and Ethnic Groups in Clinical Trials on Immune Checkpoint Inhibitors